KBC Group NV Has $245.71 Million Stock Holdings in Bristol Myers Squibb Company $BMY

KBC Group NV raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 6.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,264,357 shares of the biopharmaceutical company’s stock after acquiring an additional 254,197 shares during the period. KBC Group NV owned about 0.21% of Bristol Myers Squibb worth $245,713,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter worth $25,000. Physician Wealth Advisors Inc. boosted its holdings in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Bayban bought a new position in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 1.2%

Shares of BMY stock opened at $63.86 on Friday. The firm has a 50 day moving average price of $59.56 and a two-hundred day moving average price of $58.97. The company has a market capitalization of $130.45 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.10. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Analysts Set New Price Targets

Several equities research analysts have commented on BMY shares. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, July 30th. Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. JPMorgan Chase & Co. increased their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.